- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00753207
Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30
An Open-Label Phase I Study of Fixed Dose Lapatinib in Combination With an Escalating Dose of Epirubicin in Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with epirubicin may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of epirubicin when given together with lapatinib in treating patients with metastatic breast cancer.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- To assess the safety and tolerability of fixed-dose lapatinib ditosylate in combination with epirubicin hydrochloride in patients with metastatic breast cancer.
- To determine the optimally-tolerated regimen in these patients.
Secondary
- To determine the clinical efficacy of this regimen in these patients.
- To analyze pharmacokinetic data of this regimen.
- To determine biomarkers that correlate with clinical benefit or response to lapatinib ditosylate in these patients.
Tertiary
- To identify tumor-derived or blood-derived biomarkers that correlate with or are predictive of clinical response or benefit to lapatinib ditosylate in these patients.
- To determine the levels of IGF-IR and phosphorylated IGF-IR in tumor tissue.
- To determine the expression pattern of the proteins associated with drug resistance that may be clinically active in these patients.
OUTLINE: This is a multicenter, dose-escalation study of epirubicin hydrochloride.
Patients receive oral lapatinib ditosylate followed by epirubicin hydrochloride IV over 15-30 minutes on day 1. Treatment repeats every 3 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
Blood samples are collected periodically for pharmacokinetic analysis via liquid chromatography-mass spectometry (LC-MS).
After completion of study therapy, patients are followed at 28 days and then every 3 months thereafter.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, 8
- St James's Hospital
-
Dublin, Ireland, 4
- St Vincent's University Hospital
-
Dublin, Ireland, 24
- The Adelaide and Meath Hospital, Dublin Incorporating the National Childresn's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Confirmed diagnosis of breast cancer
- Metastatic disease
- No de novo metastasis
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy > 3 months
- Menopausal status not specified
- ANC ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Hemoglobin ≥ 9 g/dL
- Creatinine clearance ≥ 50 mL/min
- AST/ALT < 3 times upper limit of the normal (ULN)
- Total bilirubin normal (unless documented history of congenital hypobilirubinemia)
- LVEF normal by ECHO or MUGA scan
- Not pregnant or breastfeeding
- Negative pregnancy test
- Fertile patients must use effective contraception from the time of their negative pregnancy test before treatment, during treatment, and 28 days following treatment
- Able to swallow and retain oral medication
- History of other malignancies (e.g., cervical carcinoma in situ, melanoma in situ, or basal cell or squamous cell carcinoma of the skin) allowed provided patient has been treated and disease free ≥ 5 years and deemed by the investigator to be at low risk for recurrence
- No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib ditosylate or excipients
- No malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, or ulcerative colitis
- No active or uncontrolled infection
- No known history of uncontrolled or symptomatic angina, arrhythmias, congestive heart failure, or other cardiac disorders
- No history of prolonged QT interval
- No active hepatic or biliary disease (except for Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
- No concurrent disease or condition that would render the patient inappropriate for study participation, or serious medical disorder that would interfere with the patient's safety
- No dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent
PRIOR CONCURRENT THERAPY:
- Prior radiotherapy for treatment of primary tumor allowed
- Prior non-anthracycline based regimens in neoadjuvant, adjuvant, or metastatic setting allowed
- Prior adjuvant Herceptin® or ErbB inhibitors allowed provided disease progression was > 6 months after completion of treatment
- More than 3 months since prior Herceptin®, ErbB1, or ErbB2
- No prior chemotherapy in the adjuvant or neoadjuvant setting with anthracycline or anthracenedione-containing regimens
- More than 3 weeks since prior and no concurrent medications that would prolong QT interval
- More than 1 month or 5 half-lives (whichever is longer) since prior, no concurrent investigational drugs
- No unresolved or unstable, serious toxicity from prior investigational drug and/or cancer treatment
- At least 3 weeks since prior and no concurrent prohibited medications (i.e., CYP3A4 inducers or inhibitors)
- No concurrent non-study anticancer therapy (i.e., chemotherapy, immunotherapy, or biologic therapy)
- No concurrent participation in another clinical trial
- No concurrent grapefruit or grapefruit juice
- Concurrent bisphosphonates allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lapatinib and Epirubicin
Fixed dose of lapatinib in combination with escalating dose of epirubicin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Optimally-tolerated regimen of lapatinib ditosylate in combination with epirubicin hydrochloride
Time Frame: 2012
|
2012
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of this regimen in terms of objective tumor response rate and disease progression as assessed by standard RECIST criteria
Time Frame: 2012
|
2012
|
Pharmacokinetics
Time Frame: 2012
|
2012
|
Correlation between baseline expression of intra-tumoral biomarkers (e.g., ErbB1, ErbB2, insulin-like growth factor-1 receptor, p-AKT, and ERK) and clinical response or benefit to lapatinib ditosylate by IHC
Time Frame: 2012
|
2012
|
Correlation between expression pattern of drug resistance proteins (e.g., p-glycoprotein, MRP1, BCRP, and MDR-3) and clinical response or benefit to lapatinib ditosylate by IHC
Time Frame: 2012
|
2012
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-30 ICORG
- ICORG-06-30
- ICORG-109403
- EUDRACT-2007-002327-33
- EU-20875
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Haukeland University HospitalKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingSeminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular CancerNorway, Sweden
-
Centre Hospitalier Universitaire de NīmesCompletedMultiple Sclerosis | Neuromyelitis OpticaFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCTerminatedLymphoma | Nonneoplastic ConditionUnited States
-
China National Center for Cardiovascular DiseasesPeking Union Medical College HospitalRecruiting
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedPancreatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedGastrointestinal Stromal TumorUnited States
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland